August 28th 2019
Sundar Jagannath, MD, highlights the current state of the relapsed/refractory multiple myeloma paradigm and research regarding next steps for advancing treatment.
August 27th 2019
Edward B. Garon, MD, MS, highlights the 5-year KEYNOTE-001 data and also the activity with lurbinectedin in small cell lung cancer.
August 20th 2019
Pashtoon M. Kasi, MBBS, MD, MS, discusses the use of ctDNA testing throughout treatment for patients with colorectal cancer and ongoing research on liquid biopsies.
August 19th 2019
Terry L. Evans, MD, discusses the use of PARP inhibitors in ovarian cancer and how they are poised to optimally fit in the treatment paradigm.
Kerry A. Rogers, MD, highlights the findings of a study examining acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia and the next steps for the data.
August 15th 2019
Leticia Varella, MD, discusses the progression of available treatments in hormone receptor-positive, HER2-negative metastatic breast cancer.
August 14th 2019
Hope S. Rugo, MD, discusses the findings from the phase III SOPHIA trial and the potential impact of margetuximab on HER2-positive metastatic breast cancer.
August 13th 2019
Sarah E. Taylor, MD, discusses the role of somatic and germline testing for patients with ovarian cancer and their family members to create more personalized treatment and prevent disease.
August 12th 2019
Jennifer W. Carlisle, MD, highlights the research surrounding immunotherapy in frontline lung cancer treatment.
August 8th 2019
Michelle M. Boisen, MD, discusses the role of neoadjuvant chemotherapy in advanced ovarian cancer and data comparing outcomes with this modality versus upfront surgery.
August 7th 2019
Drew Moghanaki, MD, MPH, discusses the impact of the PACIFIC trial and future research in stage III non–small cell lung cancer.
Anna F. Farago, MD, PhD, discusses the second-line data with lurbinectedin and its potential impact on the small cell lung cancer field.
August 6th 2019
Eleni Andreopoulou, MD, discusses the impact of the IMpassion130 trial on TNBC treatment and the use of immunotherapy in this patient population.
August 5th 2019
Jonathan Riess, MD, MS, discusses ongoing research with PARP inhibitors in lung cancer and potential biomarkers for this class of agents.
August 2nd 2019
Lisa Newman, MD, MPH, FACS, FASCO, highlights the history and ongoing research of the genotype causing predisposition to TNBC in African-American women.
Mitchel Hoffman, MD, explains the use of surgery and neoadjuvant chemotherapy in ovarian cancer.
August 1st 2019
Hye Sook Chon, MD, discusses the progress of maintenance therapy in ovarian cancer.
July 26th 2019
Paul A. Bunn Jr, MD, highlights the benefits of preoperative window-of-opportunity studies, specifically with immunotherapy in lung cancer.
Ajai Chari, MD, discusses current and emerging research in patients with transplant-eligible and -ineligible multiple myeloma as well as updates in smoldering multiple myeloma.
July 25th 2019
Deepu Madduri, MD, discusses ongoing trials examining CAR T-cell therapy in myeloma and the potential to use it in earlier lines of therapy.